ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01125657
Recruitment Status : Completed
First Posted : May 18, 2010
Last Update Posted : May 25, 2010
Sponsor:
Information provided by:
Astellas Pharma Inc

Brief Summary:
This study is to compare its pharmacokinetics profile of two YM150 formulations by 2x2 crossover method.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Pharmacokinetics of YM150 Drug: YM150 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B -
Study Start Date : February 2010
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: formualation-A to -B sequence group Drug: YM150
oral

Experimental: formulation-B to -A sequence group Drug: YM150
oral




Primary Outcome Measures :
  1. Plasma concentration of YM150 and its metabolites measured by blood sample [ Time Frame: for 3 days after drug administration ]

Secondary Outcome Measures :
  1. Safety assessed by AEs, vital signs, 12-lead ECG and lab tests [ Time Frame: or 3 days after drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body weight: ≥50.0 kg, <80.0 kg
  • BMI: ≥17.6, <26.4
  • Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and lab tests

Exclusion Criteria:

  • Received any investigational drugs within 120 days before the study
  • Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the study
  • Received medication within 7 days before the study
  • A deviation from the assessment criteria of physical examinations or laboratory tests
  • A deviation from the normal reference range of coagulation test [PT (INR) or aPTT]
  • History of drug allergies
  • Upper gastrointestinal disease within 7 days before the study
  • Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases
  • Concurrent or previous malignant tumor
  • Previous treatment with YM150

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01125657


Locations
Japan
Kyushu, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Chair: Use Central Contact Astellas Pharma Inc

Responsible Party: Director, Astellas Pharma, Inc
ClinicalTrials.gov Identifier: NCT01125657     History of Changes
Other Study ID Numbers: 150-CL-046
First Posted: May 18, 2010    Key Record Dates
Last Update Posted: May 25, 2010
Last Verified: May 2010

Keywords provided by Astellas Pharma Inc:
YM150
bioequivalence study

Additional relevant MeSH terms:
Darexaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants